Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Publication
Video
Supplements and Featured PublicationsDiagnosis and Trial Options in Sarcoma
Volume 1
Issue 1

In Partnership With:

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate cancer center director, Experimental Therapeutics, Yale School of Medicine, discusses the importance of clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

For patients who present with MDM2-amplified dedifferentiated liposarcoma, enrolling them in a clinical trial for an MDM2 inhibitor, such as BI 907828, at a site that has a clinical trial opened, would be an ideal treatment approach, LoRusso explains. BI 907828 is an important drug for this particular tumor type with an MDM2 alteration, LoRusso adds. Moreover, BI 907828 demonstrated efficacy in a prior phase 1 trial (NCT03449381), and the soft tissue sarcoma community should be alerted to this drug, LoRusso says. 

BI 907828 is now under further investigation in the phase 2/3 Brightline-1 trial (NCT05218499) in patients with dedifferentiated liposarcoma. Patients with this MDM2 amplifications could benefit from enrollment, LoRusso concludes. 

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute